Abbott (NYSE:ABT) announced today that it launched its IonicRF generator for non-surgical treatment for nervous system pain management. The recently FDA-cleared device is designed for minimally invasive treatment through radiofrequency ablation, using heat to target specific nerves and block pain signals from reaching the brain. According to a news release. it’s the first Abbott-developed RF ablation […]
Pain Management
Nevro rises on Street-beating Q3
Nevro (NYSE:NVRO) shares ticked up today on third-quarter results that came in ahead of the consensus forecast. The Redwood City, Calif.-based chronic pain treatment developer posted losses of -$10 million, or -29¢ per share, on sales of $108.5 million for the three months ended Sept. 30, 2020, for a 44.1% bottom-line gain on sales growth of […]
Salvia BioElectronics wins FDA breakthrough nod for neurostim migraine treatment device
Dutch startup Salvia BioElectronics this week said it received FDA breakthrough device designation for its implantable neurostimulation system to treat chronic migraine. Salvia’s system is based on a novel device concept using thin and conforming bioelectronic foils that it says uniquely adapt to the anatomy of the head. “The FDA breakthrough device designation of our […]
Neuros Medical raises $37M
Neuromodulation technology developer Neuros Medical filed an SEC Form D to confirm the sale of nearly $37 million in equity. Willoughby Hills, Ohio-based Neuros Medical made the first sale in the new notice offering on Oct. 27, 2020, and listed in the SEC filing that it does not intend for it to last longer than […]
Medtronic reports positive results from spinal cord stimulation trial
Medtronic (NYSE:MDT) announced today that it posted positive 12-month results validating the superiority of its DTM spinal cord stimulation (SCS). Fridley, Minn.-based Medtronic’s multicenter, randomized controlled trial produced statistically significant 12-month data that validated the DTM SCS’ (using the Medtronic Intellis platform) superiority in providing relief for back pain when compared to conventional SCS therapy, according […]
The top 10 medical disruptors of 2021
For the past 18 years, the Cleveland Clinic has predicted what the top 10 medical disruptors will be for the following year. The list of technologies, cultivated by a panel of physicians and scientists at the clinic, was led by Dr. Will Morris, executive medical director of Cleveland Clinic Innovations, and Dr. Akhil Saklecha, managing […]
Abbott enrolls first patient in spinal cord stimulation study
Abbott (NYSE:ABT) announced that it enrolled the first patient in its Distinct study to investigate its BurstDR spinal cord stimulation (SCS). The Distinct (dorsal spinal cord stimulation vs. medical management for treatment of low back pain) study seeks to investigate the efficacy of BurstDR SCS compared with conventional medical management (CMM) in people with chronic low […]
Boston Scientific launches spinal cord stimulator systems in Europe
Boston Scientific (NYSE:BSX) announced that it launched its WaveWriter Alpha spinal cord stimulator (SCS) system portfolio in Europe. Marlborough, Mass.-based Boston Scientific’s portfolio includes four MRI-conditional, Bluetooth-enabled implantable pulse generators (IPGs) and offers expanded personalization, rechargeable and non-rechargeable options and access to waveforms covering multiple areas of pain, according to a news release. SCS therapies relieve […]
NeuroMetrix launches Quell app for Apple Watch
NeuroMetrix (NSDQ:NURO) announced that it launched the Quell Watch App for transcutaneous electrical nerve stimulation (TENS). Woburn, Mass.-based NeuroMetrix’s Quell app, which is now available for download from the Apple App Store, allows users of the Quell system to personalize and manage their therapy discreetly on iPhone and Android smartphones, according to a news release. Quell […]
FTC to refund Neurometrix consumers $3.9M in false ad case
The Federal Trade Commission announced that it is refunding NeuroMetrix (NSDQ:NURO) consumers nearly $3.9 million after false advertising. NeuroMetrix marketed its Quell transcutaneous electrical nerve stimulation device as a clinically proven and FDA-cleared treatment for widespread chronic pain relief when placed below the knee, according to the FTC, which said that the company lacks scientific evidence […]
Theranica lands CE mark for migraine device
Theranica announced today that it received CE Mark approval for its Nerivio device for the acute treatment of migraine. Montclair, N.J.-based Theranica adds European approval just over a year since it received FDA de novo clearance for the neurostimulation device in May 2019. The approval allows for the company to begin marketing the device in […]
